Skip to main content
Gain Therapeutics, Inc. logo

Gain Therapeutics, Inc. — Investor Relations & Filings

Ticker · GANX ISIN · US36269B1052 US Manufacturing
Open in API
Filings indexed 217 across all filing types
Latest filing 2021-03-16 Regulatory Filings
Country US United States of America
Listing US GANX

About Gain Therapeutics, Inc.

https://www.gaintherapeutics.com/

Gain Therapeutics, Inc. is a clinical-stage biotechnology company that discovers and develops next-generation allosteric small molecule therapies. The company utilizes its proprietary Magellan™ drug discovery platform, which combines artificial intelligence with physics-based computational models to identify novel allosteric binding sites on disease-implicated proteins. This approach aims to modulate protein function to treat diseases that are currently undruggable. The company's lead candidate, GT-02287, is in Phase I clinical trials for the treatment of GBA-Parkinson’s disease. Gain's therapeutic pipeline targets neurodegenerative diseases, lysosomal storage disorders, and other conditions with high unmet medical needs.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2021
Regulatory Filings Classification · 95% confidence The document is a letter from a law firm to the SEC responding to a comment on an Amendment No. 2 to a Registration Statement on Form S-1. It discusses revisions to corporate governance documents and disclosures related to exclusive forum provisions. The document is short (2910 characters) and is a correspondence related to a regulatory filing, not the filing itself. It does not contain financial statements or detailed financial data. It is primarily a regulatory correspondence responding to SEC comments, which fits the Regulatory Filings (RNS) category as a fallback for miscellaneous regulatory communications that do not fit other categories.
2021-03-16 English
Regulatory Filings 2021
Regulatory Filings
2021-03-16 English
Regulatory Filings 2021
Regulatory Filings Classification · 100% confidence The document is a letter from Gain Therapeutics, Inc. to the SEC requesting acceleration of the effective date of a Registration Statement on Form S-1. It references the registration of the company's Class A common stock and cites Rules 460 and 461 under the Securities Act of 1933. The document is a formal communication related to a securities registration process, not a financial report, earnings release, or other report type. It is a regulatory filing related to the registration process and does not contain financial statements or detailed financial data. The document length is short (1693 characters), and it is clearly a regulatory communication. Therefore, the appropriate classification is Regulatory Filings (RNS).
2021-03-15 English
Capital/Financing Update 2021
Capital/Financing Update Classification · 95% confidence The document is a letter addressed to the SEC requesting acceleration of the effective date for a Registration Statement on Form S-1. It references securities law rules and underwriters' compliance but does not contain financial statements or detailed financial data. The document is short (1896 characters) and is a regulatory communication related to a capital raising process, specifically a registration statement for securities issuance. This fits the category of Capital/Financing Update (CAP) rather than a full report or announcement of a report publication. Therefore, the appropriate classification is CAP.
2021-03-15 English
Regulatory Filings 2021
Regulatory Filings Classification · 95% confidence The document is a letter from a law firm to the SEC responding to comments on an Amendment No. 1 to a Registration Statement on Form S-1, with references to revisions made in Amendment No. 2. It discusses SEC staff comments on financial disclosures, stock splits, and footnotes related to a registration statement filing. The document is a correspondence related to a regulatory filing process, specifically an amendment to a registration statement, and does not contain financial statements or detailed financial data itself. It is also relatively short (3402 characters) and serves as a response letter rather than a full report. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements, compliance documents, and correspondence with regulators that do not fit other categories.
2021-03-15 English
S-1/A
Capital/Financing Update Classification · 100% confidence The document is an Amendment No. 2 to a Form S-1 Registration Statement filed with the SEC under the Securities Act of 1933. It is a registration statement for an initial public offering (IPO) of common stock by Gain Therapeutics, Inc. The document includes detailed information typical of an S-1 filing such as company background, risk factors, use of proceeds, capitalization, dilution, management discussion and analysis, executive compensation, principal stockholders, and underwriting details. It is not a financial report like an annual or quarterly report, nor is it a proxy, earnings release, or other types of filings. The S-1 registration statement is a capital markets filing related to the company's offering of securities to the public. According to the provided filing categories, the closest and most appropriate classification for an SEC registration statement S-1 is Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities.
2021-03-15 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.